Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that U.S. Renal Care (USRC), the nation’s largest privately held and fastest-growing kidney care provider, presented data from the Vafseo Outcomes In Center Experience (VOICE) trial during a late-breaking session at American Society of Nephrology Kidney Week 2026 (ASN Kidney Week). The presentation highlighted findings of significantly improved safety outcomes in patients treated with vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) dosed three times weekly (TIW) versus an erythropoiesis-stimulating agent (ESA). Additional data showed more stable hemoglobin control and fewer serious adverse events in the patients treated with vadadustat.

In March 2024, Vafseo® (vadadustat), was approved by the U.S. Food and Drug Administration for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and it has been available in the U.S. since January 2025. Vafseo is approved for once-daily administration. There are no other oral HIF-PHIs to treat anemia in the market or in development in the U.S.